A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck.

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508561-33-00

Acronym

TG4050.02

Enrollment

Registered

2023-12-06

Start date

2019-12-12

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV negative, hypopharynx or larynx (SCCHN) for patients who have completed and a documented complete response to gross total resection of the primary tumor and standard adjuvant therapy., Newly diagnosed, oropharynx, squamous-cell carcinoma of the oral cavity, stage III or IV amenable to surgery

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Spain

Outcome results